Keyphrases
Randomized Controlled Trial
100%
Type 2 Diabetic Patients
100%
High Cardiovascular Risk
100%
Hemodynamic Effects
100%
Empagliflozin
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
75%
Cardiovascular Events
50%
Placebo
50%
Pulmonary Capillary Wedge Pressure
50%
Submaximal Exercise
50%
Randomized Placebo-controlled Trial
25%
Clinical Significance
25%
Once-daily
25%
Patients with Diabetes
25%
Hemodynamic Assessment
25%
Double-blind Trial
25%
Ergometer
25%
Filling Pressure
25%
Right Heart Catheterization
25%
Central Hemodynamics
25%
Investigator-initiated
25%
Left Heart
25%
Medicine and Dentistry
Randomized Controlled Trial
100%
Cardiovascular Risk
100%
Patient with Type 2 Diabetes
100%
Hemodynamic
100%
Empagliflozin
100%
Placebo
75%
Sodium Glucose Cotransporter 2 Inhibitor
75%
Cardiovascular System
50%
Pulmonary Artery Occlusion Pressure
50%
Clinical Significance
25%
Patient with Diabetes
25%
Cardiac Catheterization
25%